Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) EBIAT: 2009-2021

Historic EBIAT for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Dec 2021 value amounting to -$23.1 million.

  • Avadel Pharmaceuticals' EBIAT fell 105.14% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$88.2 million, marking a year-over-year decrease of 157.73%. This contributed to the annual value of -$85.5 million for FY2021, which is 1317.22% down from last year.
  • As of Q4 2021, Avadel Pharmaceuticals' EBIAT stood at -$23.1 million, which was up 9.85% from -$25.7 million recorded in Q3 2021.
  • In the past 5 years, Avadel Pharmaceuticals' EBIAT ranged from a high of $28.9 million in Q2 2017 and a low of -$63.9 million during Q4 2018.
  • Moreover, its 3-year median value for EBIAT was -$11.5 million (2020), whereas its average is -$13.0 million.
  • Its EBIAT has fluctuated over the past 5 years, first surged by 527.70% in 2017, then tumbled by 2,598.96% in 2021.
  • Over the past 5 years, Avadel Pharmaceuticals' EBIAT (Quarterly) stood at -$8.2 million in 2017, then tumbled by 674.52% to -$63.9 million in 2018, then surged by 95.71% to -$2.7 million in 2019, then plummeted by 311.76% to -$11.3 million in 2020, then plummeted by 105.14% to -$23.1 million in 2021.
  • Its last three reported values are -$23.1 million in Q4 2021, -$25.7 million for Q3 2021, and -$23.3 million during Q2 2021.